US patent for identifying drugs for abnormal kidney function

Proteomics International has been granted a new patent that has important longer-term potential value to our company.

The patent concerns the use of one of the core PromarkerD biomarkers as a potential novel therapeutic drug target in the treatment of kidney disease. There are no drugs currently available specifically for kidney disease and developing news drugs in this area has proved a challenge for the pharmaceutical industry.

Whilst further research is required to confirm the viability of our biomarker as a drug target, any pharmaceutical company in the USA seeking to develop a treatment using this novel target will need to reach commercial agreement with Proteomics International.

Media release

  • This field is for validation purposes and should be left unchanged.